Imexpharm Corporation (HOSE:IMP)

Market Cap	7.92T
Revenue (ttm)	2.31T
Net Income (ttm)	309.16B
Shares Out	154.01M
EPS (ttm)	2,007.45
PE Ratio	25.60
Forward PE	n/a
Dividend	500.00 (0.97%)
Ex-Dividend Date	Jun 9, 2025

Volume	44,904
Average Volume	105,172
Open	51,600
Previous Close	51,200
Day's Range	50,700 - 51,600
52-Week Range	33,636 - 56,500
Beta	0.75
RSI	54.97
Earnings Date	Jul 18, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 7.11%.